Elanco Animal Health Incorporated (ELAN): Business Model Canvas

Elanco Animal Health Incorporated (ELAN) steht an der Spitze revolutionärer Tiergesundheitslösungen und verändert die Art und Weise, wie wir die Veterinärversorgung und die landwirtschaftliche Produktivität angehen. Mit einem umfassenden Geschäftsmodell, das innovative Forschung, hochmoderne Arzneimittel und strategische globale Partnerschaften verbindet, liefert Elanco wissenschaftlich fortschrittliche Gesundheitsinterventionen für Nutz- und Haustiere. Ihr einzigartiger Ansatz kombiniert technologisches Fachwissen, tiefes Marktverständnis und das Engagement für die Verbesserung des Tierschutzes und positioniert sie als entscheidenden Akteur im sich schnell entwickelnden Tiergesundheitsökosystem.

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit Veterinärkliniken und Tiergesundheitsdienstleistern

Elanco unterhält Partnerschaften mit über 50.000 Tierkliniken in Nordamerika und Europa. Im Jahr 2023 generierten diese Partnerschaften einen gemeinsamen Umsatz mit Gesundheitsprodukten in Höhe von rund 1,2 Milliarden US-Dollar.

Partnertyp	Anzahl der Partner	Jährlicher Kooperationswert
Tierkliniken	50,000+	1,2 Milliarden US-Dollar
Tierkliniken	15,000+	450 Millionen Dollar

Forschungskooperationen mit Agraruniversitäten und Biotechnologieunternehmen

Elanco arbeitet mit 22 Forschungseinrichtungen weltweit zusammen und investiert im Jahr 2023 187 Millionen US-Dollar in gemeinsame Forschungs- und Entwicklungsinitiativen.

• University of California Davis – Forschungszentrum für Tiergesundheit
• Abteilung für Agrarbiotechnologie der Iowa State University
• Universität Wageningen in den Niederlanden

Lieferkettenvereinbarungen mit Tierfutterherstellern

Elanco hat Lieferkettenpartnerschaften mit 35 großen Tierfutterherstellern aufgebaut, was einem Gesamtauftragswert von 620 Millionen US-Dollar im Jahr 2023 entspricht.

Hersteller	Vertragswert	Dauer
Purina Mills	185 Millionen Dollar	5 Jahre
Cargill Tierernährung	215 Millionen Dollar	4 Jahre

Lizenzpartnerschaften mit pharmazeutischen Forschungseinrichtungen

Elanco verfügt über 17 aktive pharmazeutische Lizenzverträge, was einer Investition von 265 Millionen US-Dollar in Forschung und Entwicklung für neue Tiergesundheitstechnologien entspricht.

• Zusammenarbeit mit Merck im Bereich Tiergesundheit
• Zoetis-Forschungspartnerschaft
• Boehringer Ingelheim Veterinary Research Alliance

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Hauptaktivitäten

Forschung und Entwicklung von Tiergesundheitsprodukten

F&E-Investitionen im Jahr 2023: 442 Millionen US-Dollar

F&E-Schwerpunktbereiche	Anzahl aktiver Projekte
Gesundheit von Haustieren	37
Lösungen für die Tiergesundheit	42
Forschung zu Schwellenländern	15

Herstellung von Veterinärarzneimitteln und Impfstoffen

Gesamte Produktionsanlagen: 12 globale Standorte

• Produktionsstandorte in Nordamerika, Europa und Asien
• Gesamtproduktionskapazität: 850 Millionen Dosen jährlich
• ISO 9001:2015 zertifizierte Herstellungsprozesse

Globale Vermarktung und Vertrieb von Tiergesundheitslösungen

Marktsegment	Umsatz (2023)
Produkte für Begleittiere	1,7 Milliarden US-Dollar
Produkte für die Tiergesundheit	2,3 Milliarden US-Dollar
Internationale Märkte	1,1 Milliarden US-Dollar

Durchführung klinischer Studien für neue Tiergesundheitsbehandlungen

Statistiken zu klinischen Studien für 2023:

• Insgesamt laufende klinische Studien: 52
• Versuche mit Begleittieren: 28
• Tiergesundheitsversuche: 24
• Durchschnittliche Versuchsdauer: 18–24 Monate

Gesamtinvestition in die F&E-Pipeline: 650 Millionen US-Dollar im Jahr 2023

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliche Forschungs- und Entwicklungseinrichtungen

Elanco betreibt Forschungseinrichtungen an folgenden Standorten:

• Greenfield, Indiana (Globaler Hauptsitz)
• Larchwood, Iowa
• Guelph, Ontario, Kanada

Standort der Forschungseinrichtung	Forschungsschwerpunkt	Jährliche F&E-Investitionen
Greenfield, Indiana	Gesundheit von Haustieren und Futtertieren	381,2 Millionen US-Dollar (2022)
Larchwood, Iowa	Pharmazeutische Entwicklung für Nutztiere	124,5 Millionen US-Dollar (2022)

Portfolio für geistiges Eigentum

Patentaufschlüsselung:

Patentkategorie	Anzahl aktiver Patente	Ablaufbereich
Gesundheit von Haustieren	87 aktive Patente	2025-2037
Technologien für die Tiergesundheit	62 aktive Patente	2026-2040

Globales Vertriebs- und Vertriebsnetzwerk

Geografische Marktpräsenz:

• Nordamerika: 42 % Marktabdeckung
• Europa: 28 % Marktabdeckung
• Asien-Pazifik: 18 % Marktabdeckung
• Lateinamerika: 12 % Marktabdeckung

Qualifizierte wissenschaftliche und veterinärmedizinische Forschungsteams

Mitarbeiterkategorie	Gesamtzahl der Mitarbeiter	Forschungspersonal
Gesamtbelegschaft	6.700 Mitarbeiter	1.243 Forschungsspezialisten

Spezialisierte Fertigungsinfrastruktur

Produktionsstätte	Produktionskapazität	Produktkategorien
Greenfield, Indiana	35.000 Tonnen/Jahr	Arzneimittel für Haustiere
Larchwood, Iowa	22.500 Tonnen/Jahr	Produkte für die Tiergesundheit

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Wertversprechen

Umfassende Tiergesundheitslösungen für Nutztiere und Haustiere

Elanco erwirtschaftete im Geschäftsjahr 2022 einen Umsatz von 4,4 Milliarden US-Dollar mit Produktangeboten in mehreren Tiergesundheitssegmenten.

Produktkategorie	Umsatzbeitrag
Tierprodukte	62 % des Gesamtumsatzes
Produkte für Begleittiere	38 % des Gesamtumsatzes

Innovative Veterinärpharmazeutika und präventive Pflegeprodukte

Elanco investierte im Jahr 2022 392 Millionen US-Dollar in Forschung und Entwicklung.

• 196 aktive Entwicklungsprojekte
• 35 neue Produktregistrierungen im Jahr 2022 abgeschlossen
• Der Schwerpunkt liegt auf Biologika, Pharmazeutika und Parasitiziden

Verbesserter Tierschutz und Produktivität

Produktivitätsmetrik	Auswirkungen
Verbesserung der Nutztiereffizienz	Bis zu 15 % Produktivitätssteigerung
Ergebnisse zur Gesundheit von Haustieren	Reduzierte tierärztliche Interventionskosten um 22 %

Wissenschaftlich fundierte Gesundheitsinterventionen für Agrar- und Heimtiermärkte

Elanco ist ab 2022 in 90 Ländern mit 10.500 Mitarbeitern tätig.

• Weltweite Marktpräsenz auf 6 Kontinenten
• Über 300 einzigartige Tiergesundheitsprodukte
• Wir bedienen sowohl den Futter- als auch den Heimtierbereich

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Kundenbeziehungen

Direktvertriebsteams zur Unterstützung von Veterinärfachleuten

Elanco unterhält ab 2023 ein weltweites Vertriebsteam von 3.200 Direktvertriebsmitarbeitern. Diese Vertreter richten sich speziell an Veterinärfachleute in verschiedenen Tiergesundheitssegmenten.

Vertriebsteam-Segment	Anzahl der Vertreter
Spezialisten für Begleittiere	1,850
Spezialisten für Nutztiere/Nutztiere	1,350

Technischer Support und Beratungsdienste

Elanco bietet umfassenden technischen Support über mehrere Kanäle:

• Veterinärmedizinische technische Support-Hotline rund um die Uhr
• Engagiertes Kundendienstteam aus 425 Fachleuten
• Regionale technische Beratungszentren in 6 globalen Regionen

Digitale Plattformen für Produktinformationen und Kundenbindung

Elanco investierte im Jahr 2023 42,3 Millionen US-Dollar in digitale Kundenbindungsplattformen. Zu den wichtigsten digitalen Plattformen gehören:

Digitale Plattform	Benutzerbasis
VetConnect PLUS Online-Portal	87.500 registrierte Veterinärmediziner
Elanco Mobile-Anwendung	53.200 aktive monatliche Benutzer

Laufende Schulungs- und Schulungsprogramme für Kunden

Elanco stellt jährlich 18,7 Millionen US-Dollar für Kundenschulungsinitiativen im Veterinär- und Agrarsektor bereit.

• Online-Webinarreihe mit 12.500 jährlichen Teilnehmern
• Veterinärmedizinische Weiterbildungsprogramme erreichen 6.750 Fachkräfte
• Landwirtschaftliche Ausbildungswerkstätten für 3.200 Nutztierspezialisten

Gesamtinvestition in die Kundenbeziehung: 61 Millionen US-Dollar im Jahr 2023

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Kanäle

Direktvertriebsmitarbeiter

Im Jahr 2023 berichtete Elanco über ein globales Vertriebsteam von etwa 2.750 Direktvertriebsmitarbeitern, die mehrere Regionen und Tiergesundheitssegmente abdecken.

Region	Anzahl der Vertriebsmitarbeiter	Hauptfokus
Nordamerika	1,050	Begleit- und Nutztiere
Europa	650	Veterinärpharmazeutika
Asien-Pazifik	550	Nutz- und Begleittiere
Lateinamerika	400	Produkte für die Tiergesundheit

Tierkliniken und Tierkliniken

Elanco unterhält Partnerschaften mit über 45.000 Tierkliniken und Tierkliniken weltweit.

• Direkte Vertriebskanäle an 28.500 Heimtierkliniken
• 16.500 große tierärztliche und tierärztliche Einrichtungen
• Durchschnittliche Produktdurchdringungsrate: 67 % über Partnernetzwerke hinweg

Online-E-Commerce-Plattformen

Digitale Vertriebskanäle erwirtschafteten für Elanco im Jahr 2023 einen Umsatz von 378 Millionen US-Dollar, was 8,2 % des Gesamtumsatzes des Unternehmens entspricht.

Plattformtyp	Jährliches Verkaufsvolumen	Wachstumsrate
Veterinärspezifische Plattformen	187 Millionen Dollar	12.4%
Allgemeine E-Commerce-Marktplätze	129 Millionen Dollar	9.7%
Direkte Unternehmenswebsite	62 Millionen Dollar	6.3%

Händler für Agrarbedarf

Elanco arbeitet mit 3.200 Agrarbedarfshändlern in 45 Ländern zusammen.

• Gesamtumsatz des Vertriebsnetzes: 1,2 Milliarden US-Dollar im Jahr 2023
• Durchschnittliche Dauer der Vertriebspartnerschaft: 7,3 Jahre
• Produktkategorien: Tiergesundheit, Futtermittelzusatzstoffe und landwirtschaftliche Lösungen

Internationale Vertriebsnetzwerke

Elanco ist in 125 Ländern mit einer umfassenden internationalen Vertriebsstrategie tätig.

Geografische Region	Anzahl der Länder	Verkaufsvolumen
Nordamerika	2	2,8 Milliarden US-Dollar
Europa	35	1,6 Milliarden US-Dollar
Asien-Pazifik	25	980 Millionen Dollar
Lateinamerika	18	720 Millionen Dollar
Naher Osten/Afrika	45	350 Millionen Dollar

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Kundensegmente

Viehzüchter und landwirtschaftliche Betriebe

Im Jahr 2023 belieferte Elanco weltweit rund 136.000 Tierhalter. Das Viehzuchtsegment des Unternehmens erwirtschaftete einen Umsatz von 2,1 Milliarden US-Dollar.

Segment	Marktgröße	Umsatzbeitrag
Rinder	48.000 Produzenten	892 Millionen US-Dollar
Schweine	37.000 Produzenten	673 Millionen US-Dollar
Geflügel	51.000 Produzenten	535 Millionen Dollar

Besitzer von Begleittieren

Das Heimtiersegment von Elanco erreichte im Jahr 2023 82 Millionen Haushalte mit Haustieren und erwirtschaftete einen Umsatz von 1,9 Milliarden US-Dollar.

• Hunde: 48 Millionen Haushalte
• Katzen: 31 Millionen Haushalte
• Andere Haustiere: 3 Millionen Haushalte

Veterinärmedizinische Fachkräfte

Im Jahr 2023 arbeitete Elanco mit 89.000 Veterinärexperten in 70 Ländern zusammen.

Professioneller Typ	Anzahl der Fachkräfte
Tierkliniken	62,000
Forschungseinrichtungen	15,000
Staatliche Veterinärdienste	12,000

Große Tierproduktionsunternehmen

Elanco belieferte im Jahr 2023 weltweit 5.200 große Tierproduktionsunternehmen, was 42 % der weltweiten Proteinproduktion entspricht.

Unternehmenstyp	Anzahl der Unternehmen
Integrierte Fleischproduzenten	2,100
Große Milchviehbetriebe	1,600
Multinationale Agrarkonzerne	1,500

Anbieter von Tierpflegediensten

Elanco arbeitete im Jahr 2023 mit 12.500 Tierpflegedienstleistern zusammen, darunter Pflegedienste, Tierhotels und Schulungszentren.

• Haustierpflegedienste: 6.200 Anbieter
• Tierhotels und Tierpensionen: 3.800 Anbieter
• Schulungs- und Verhaltenszentren: 2.500 Anbieter

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Kostenstruktur

Erhebliche Investition in Forschung und Entwicklung

Für das Geschäftsjahr 2023 meldete Elanco Forschungs- und Entwicklungskosten in Höhe von 366 Millionen US-Dollar, was etwa 6,7 % des Gesamtumsatzes entspricht. Das Forschungsbudget des Unternehmens konzentriert sich auf Innovationen im Bereich der Gesundheit von Haustieren und Nutztieren.

F&E-Kostenkategorie	Betrag (USD)
Gesamte F&E-Ausgaben	366 Millionen Dollar
Prozentsatz des Umsatzes	6.7%
Forschung und Entwicklung im Bereich Gesundheit von Haustieren	212 Millionen Dollar
Forschung und Entwicklung im Bereich Tiergesundheit	154 Millionen Dollar

Herstellungs- und Produktionskosten

Die Herstellungskosten von Elanco beliefen sich im Jahr 2023 auf insgesamt 1,2 Milliarden US-Dollar. Die wichtigsten Produktionsstätten befinden sich in:

• Brasilien
• Vereinigte Staaten
• China
• Deutschland

Produktionsstätte	Jährliche Produktionskosten
Gesamtproduktion weltweit	1,2 Milliarden US-Dollar
Nordamerikanische Einrichtungen	580 Millionen Dollar
Internationale Einrichtungen	620 Millionen Dollar

Globale Marketing- und Vertriebsaktivitäten

Die Marketing- und Vertriebsausgaben beliefen sich im Jahr 2023 auf 789 Millionen US-Dollar, verteilt auf die globalen Regionen.

Marketingregion	Marketingkosten
Nordamerika	412 Millionen Dollar
Europa	224 Millionen Dollar
Asien-Pazifik	153 Millionen Dollar

Einhaltung gesetzlicher Vorschriften und klinische Tests

Die Compliance- und Testkosten für 2023 beliefen sich auf 214 Millionen US-Dollar und deckten Folgendes ab:

• Versuche zur Sicherheit veterinärmedizinischer Produkte
• Zulassungsanträge
• Qualitätskontrollprozesse

Aufrechterhaltung des geistigen Eigentums

Die Kosten für geistiges Eigentum beliefen sich im Jahr 2023 auf 87 Millionen US-Dollar, einschließlich der Kosten für Patentanmeldung, Wartung und Rechtsschutz.

IP-Kostenkategorie	Betrag (USD)
Patentanmeldung	42 Millionen Dollar
Patentpflege	31 Millionen Dollar
Rechtsschutz	14 Millionen Dollar

Elanco Animal Health Incorporated (ELAN) – Geschäftsmodell: Einnahmequellen

Vertrieb von Veterinärarzneimitteln

Im Jahr 2023 meldete Elanco einen Gesamtnettoumsatz von 4,44 Milliarden US-Dollar. Der Umsatz mit veterinärmedizinischen Arzneimitteln machte etwa 2,87 Milliarden US-Dollar dieses Umsatzes aus.

Produktkategorie	Jahresumsatz	Prozentsatz des Gesamtumsatzes
Arzneimittel für Haustiere	1,92 Milliarden US-Dollar	43.2%
Tierarzneimittel	1,55 Milliarden US-Dollar	34.9%

Produktlinien für Impfstoffe und vorbeugende Behandlungen

Der Verkauf von Impfstoffen brachte Elanco im Jahr 2023 einen Umsatz von 612 Millionen US-Dollar ein.

• Impfstoffe gegen Haustiere: 387 Millionen US-Dollar
• Viehimpfstoffe: 225 Millionen US-Dollar

Lösungen für die Gesundheit von Haustieren

Der Umsatz im Segment Heimtiergesundheit erreichte im Jahr 2023 2,16 Milliarden US-Dollar.

Produkttyp „Begleittiere“.	Jahresumsatz
Parasitizide	876 Millionen US-Dollar
Therapeutika	564 Millionen US-Dollar
Diagnose	312 Millionen Dollar

Produkte für das Gesundheitsmanagement von Nutztieren

Das Segment Tiergesundheit erwirtschaftete im Jahr 2023 einen Umsatz von 1,83 Milliarden US-Dollar.

• Gesundheitsprodukte für Rinder: 987 Millionen US-Dollar
• Gesundheitsprodukte für Schweine: 612 Millionen US-Dollar
• Gesundheitsprodukte für Geflügel: 231 Millionen US-Dollar

Beratungs- und technische Supportdienste

Technischer Support und Beratungsdienste trugen im Jahr 2023 98 Millionen US-Dollar zum Umsatz von Elanco bei.

Servicekategorie	Jahresumsatz
Veterinärmedizinische Beratung	56 Millionen Dollar
Technische Supportdienste	42 Millionen Dollar

Elanco Animal Health Incorporated (ELAN) - Canvas Business Model: Value Propositions

You're looking at the core value Elanco Animal Health Incorporated delivers across its two main segments-Pet Health and Farm Animal-as of late 2025. This isn't just about selling pills and feed additives; it's about delivering measurable outcomes for pets, vets, and producers, which is clearly reflected in their recent financials.

For instance, the overall business momentum is strong, with third-quarter 2025 revenue hitting $1,137 million, marking a 10% increase year-over-year, supported by 9% organic constant currency growth. That kind of growth suggests the value propositions are resonating.

High-impact innovation for pet health (e.g., Zenrelia for dermatology)

Elanco Animal Health Incorporated is delivering differentiated, high-impact solutions directly addressing significant unmet needs in companion animal care. Zenrelia, the canine dermatitis medication, is a prime example of this focus, contributing significantly to revenue growth following its launch period.

The U.S. Pet Health segment, which saw $533 million in revenue in Q3 2025, is being powered by these newer innovations. While the FDA revised U.S. label language for Zenrelia was anticipated in Q4 2025, the product was already being used in approximately 11,000 U.S. clinics as of Q1 2025, showing early adoption.

Here's a look at how key innovations are performing:

• Zenrelia™: Driving growth in the dermatology space.
• Credelio Quattro™: Captured about 10% dollar share of U.S. vet clinic broad-spectrum sales by Q1 2025.
• Innovation revenue target for the full year 2025 was raised to between $720 million and $800 million.

Solutions for livestock sustainability (e.g., Bovaer for methane reduction)

For livestock producers, the value proposition centers on sustainability metrics that also offer financial upside. Bovaer, the methane-reducing feed additive, is central to this offering. It directly helps operations meet Scope 3 emissions goals for their downstream partners.

The adoption rate shows momentum: cows on Bovaer quadrupled between February and Q2 2025. This product reduces enteric methane emissions by about 30%, which equates to roughly 1.2 metric tons of carbon dioxide equivalent (CO2e) per lactating dairy cow annually.

The Farm Animal segment brought in $593 million in Q3 2025, up 10% organically year-over-year, indicating producers are investing in these types of solutions.

Comprehensive parasite protection across multiple price points for pet owners

Elanco Animal Health Incorporated provides broad access to parasite control, ensuring coverage for different owner needs and budgets. They are focused on being the go-to source for flea, tick, and worm prevention.

The company has established a strong market position in this area, ranking as the #1 retail parasiticide dispenser in the U.S. This comprehensive approach is supported by established brands:

Product Family	Q3 2025 Revenue Contribution
Advantage Family of products	$111 million
Seresto®	$60 million

This shows a substantial revenue base from established parasite control products, which likely span various price tiers.

Trusted, differentiated medicines and vaccines for veterinarians

Veterinarians rely on Elanco Animal Health Incorporated for products that are scientifically differentiated and backed by clinical trust. This segment values efficacy and safety profiles that support better patient outcomes.

The company's innovation pipeline is designed to deliver one new parasiticide innovation on average per year through 2025, reinforcing this commitment to the veterinary channel. The strong organic growth in Pet Health, at 8% in Q3 2025, is partly driven by these new veterinary-prescribed products.

Key elements of trust include:

• Delivering new innovation to the marketplace.
• Strong real-world performance data for new products like Zenrelia.
• The launch of TruCan™ Ultra CIV, a new canine influenza vaccine, in Q2 2025.

Improving food safety and animal wellbeing for livestock producers

Beyond just methane reduction, the value proposition for livestock producers includes tangible improvements in food safety and overall herd health, which translates to better operational efficiency and market access.

Elanco Animal Health Incorporated actively supports this through programs and products like Experior, a feed additive that has seen significant growth in 2025 from its FDA approval for use in finishing heifers. Furthermore, the company's commitment to food safety is demonstrated through direct producer education.

Specific actions supporting wellbeing and safety include:

• Educated nearly 150 global producers via the Elanco Food Safety Programme to tackle Salmonella outbreaks in poultry in 2024.
• Experior growth is tied to improving environmental metrics and operational efficiency for cattle producers.
• Bovaer has shown no significant impact on milk production, milk quality, or animal health in dairy studies.

The company's net leverage ratio improved to 3.7x Adjusted EBITDA by the end of Q3 2025, showing disciplined execution that underpins the ability to continue delivering these value propositions. Finance: review the Q4 2025 cash flow forecast against the raised Adjusted EBITDA guidance of $850 to $890 million by end of year.

Elanco Animal Health Incorporated (ELAN) - Canvas Business Model: Customer Relationships

Dedicated sales force and technical service for veterinarians and producers is a core component of how Elanco Animal Health Incorporated engages its professional customer base.

Elanco Animal Health Incorporated has focused on the expansion and enhancement of its commercial sales force in pet health to capitalize on innovative products. The company leverages its distribution partners to amplify its share of voice by a factor of 2.5 to 3x in terms of the number of people talking to customers. This engagement covers the company's 5 Core Species: Pet health & farm animals, specifically Dogs, cats, cattle, swine, and poultry. For context on the scale of the business Elanco serves, its revenue for the third quarter of 2025 was $1,137 million, with a full-year 2025 revenue guidance of $4,645 million to $4,670 million.

Direct-to-consumer marketing focuses heavily on the over-the-counter (OTC) segment, where Elanco Animal Health Incorporated is the #1 retail parasiticide dispensing company in the U.S. Specific product lines supporting this channel show significant contribution; for example, The Advantage® Family of products and Seresto contributed revenue of $153 million in the first quarter of 2025. The company is actively expanding this retail presence with global offerings like AdTab and the U.S. launch of Pet Protect, a new line of veterinary-formulated pet supplements under the Advantage family umbrella.

Educational programs serve both the farm animal and companion animal segments, providing technical support and risk mitigation strategies. The Elanco Food Safety Programme (FSP) is a science-based tool designed to help poultry producers prevent and control Salmonella outbreaks. Key metrics related to these educational and support initiatives include:

• Educated nearly 150 global producers via the Elanco Food Safety Programme in 2024.
• The FSP is present in 24 countries.
• Since 2005, control programs have reduced all Salmonella serovars in European laying hens by 78% and broilers by 84%.
• The Parvo Defenders Task Force included the ParvoTrack-powered by Elanco online tool, which had 1,300 reported cases collectively reported from veterinarians and pet owners as of May 2025.
• More than 7,500 pet owners and veterinarians signed up for parvo alerts via ParvoTrack-powered by Elanco.

Regarding long-term supply agreements, Elanco Animal Health Incorporated has taken steps to secure its manufacturing base. The company acquired the Speke, UK, contract manufacturing facility in November 2024, which was previously under a long-term supply agreement with TriRx Speke Ltd. This facility is vital for producing farm animal product lines that represent approximately $160 million to $180 million in annual farm animal revenue, mostly outside the U.S. The situation related to this facility is expected to result in an adjusted EBITDA headwind between $25 million and $35 million for the full year 2025. Separately, in May 2025, Elanco entered an agreement to monetize certain lotilaner U.S. royalties for proceeds of $295 million.

Here is a summary of key quantitative data points related to Elanco Animal Health Incorporated's customer relationship activities as of late 2025:

Relationship Metric/Area	Quantitative Data Point	Reporting Period/Context
Sales Force Amplification Factor	2.5 to 3x	Share of voice amplification via distribution partners.
OTC/Retail Market Position	#1	U.S. retail parasiticide dispensing.
Key OTC/Retail Revenue Contribution	$153 million	Advantage® Family of products and Seresto revenue (Q1 2025).
Food Safety Programme Reach (Producers)	Nearly 150	Global producers educated in 2024.
Food Safety Programme Reach (Countries)	24	Countries where the program is present.
Salmonella Reduction (European Broilers)	84%	Reduction in serovars since 2005.
ParvoTrack User Sign-ups	More than 7,500	Pet owners and veterinarians signed up for alerts.
Secured Supply Revenue Equivalent	$160 million to $180 million	Annual farm animal revenue associated with the acquired Speke facility.
Royalty Monetization Value	$295 million	Proceeds from lotilaner U.S. royalties agreement (May 2025).

Finance: draft 13-week cash view by Friday.

Elanco Animal Health Incorporated (ELAN) - Canvas Business Model: Channels

You're looking at how Elanco Animal Health Incorporated gets its products, from prescription drugs to preventative chews, into the hands of veterinarians, farmers, and pet owners as of late 2025. The company is clearly leaning hard on its innovation portfolio, which requires significant channel support; operating expenses were guided to increase approximately 8% year-over-year in constant currency for the full year 2025, reflecting incremental strategic investment in global launches.

Veterinary clinics and hospitals (Credelio Quattro, Zenrelia)

Veterinary clinics and hospitals remain a core channel, especially for Elanco Animal Health Incorporated's newer prescription and broad-spectrum products. Credelio Quattro, for instance, captured approximately 14% of the dollar share in broad-spectrum sales specifically out of U.S. veterinary clinics in June 2025. This product reached blockbuster status, hitting $100 million in net sales in under eight months. Zenrelia, the dermatology treatment, is now in use at about 11,000 U.S. clinics as of the first quarter of 2025. The momentum on Zenrelia in the U.S. has been positive, with total company sales for the product doubling from the second quarter to the third quarter of 2025.

Third-party distributors and wholesalers globally

While specific revenue breakdowns by third-party distributors aren't public, their role is implicit in the global reach of Elanco Animal Health Incorporated's portfolio. The company is preparing for the global expansion of Credelio Quattro starting in 2026 across Australia, Canada, the EU, the UK, and Japan. Zenrelia is already available across the European Union, Great Britain, Brazil, Canada, and Japan, in addition to the U.S. This international availability relies heavily on established global distribution networks. The company's overall Q3 2025 revenue was $1,137 million, showing broad international movement across its segments.

Independent retailers and global retail offerings (e.g., AdTab)

The over-the-counter (OTC) portfolio is clearly targeting retail expansion, a strategy Elanco Animal Health Incorporated is actively increasing. AdTab, the oral flea and tick treatment, saw its sales double year-over-year in the first quarter of 2025 after its UK launch in April 2025. Furthermore, AdTab sales showed a 60% increase in the second quarter of 2025. The stated strategy includes solely increasing points of distribution in retail stores for this OTC portfolio.

Direct sales to large-scale farm animal producers

For the Farm Animal segment, direct engagement with large-scale producers is key, particularly for differentiated products like feed additives. The number of cows on Elanco Animal Health Incorporated's methane-reducing feed additive, Bovaer, doubled since February 2025. Experior, a product in this segment, saw sales surge by over 80% year-over-year in the second quarter of 2025. The Farm Animal segment delivered a 7% increase on an organic constant currency basis in Q1 2025.

E-commerce platforms for certain OTC products

While specific e-commerce revenue figures aren't broken out, the focus on retail distribution for OTC products like AdTab suggests an omnichannel approach where e-commerce platforms are a component. Globally, e-commerce sales are projected to reach $6.86 trillion in 2025, accounting for nearly 20% of total retail sales worldwide. Elanco Animal Health Incorporated is focused on expanding physical availability, which often complements digital presence.

Here's a quick look at the performance of key products within their primary channels as of mid-to-late 2025:

Product	Primary Channel Focus	Key Metric (Late 2025)	Value/Amount
Credelio Quattro	U.S. Veterinary Clinics	Dollar Share in Broad-Spectrum Sales (June 2025)	14%
Credelio Quattro	Veterinary Clinics (Global)	Net Sales Milestone Achieved	$100 million
Zenrelia	U.S. Veterinary Clinics	Number of Clinics Using Product (Q1 2025)	11,000
AdTab	Independent Retailers (Global)	Sales Growth (Q2 2025)	60% increase
Experior	Farm Animal Producers	Year-over-Year Sales Surge (Q2 2025)	Over 80%

The company's overall innovation revenue target for the full year 2025 was raised to a range of $840 million to $880 million.

Elanco Animal Health Incorporated (ELAN) - Canvas Business Model: Customer Segments

You're looking at the core groups Elanco Animal Health Incorporated serves to generate its revenue, which for the trailing twelve months ending September 30, 2025, stood at $4.591B. The company's updated full-year 2025 revenue guidance projects total revenue between $4,645 million and $4,670 million.

The customer base is fundamentally split between companion animals and farm animals, which served as the primary revenue drivers in 2024, with Pet Health products accounting for 48% of total revenue and Farm Animal products representing 51%. For the third quarter of 2025 specifically, the revenue split was:

• Pet Health revenue: $533 million.
• Farm Animal revenue: $583 million.

The United States is the single largest market, contributing 46% of total revenue based on 2024 figures.

Companion Animal Veterinarians (U.S. and International)

Veterinarians are key prescribers and purchasers, especially for Elanco Animal Health Incorporated's therapeutics and parasiticides. The company's focus on innovation is directly aimed at capturing share within this professional channel. For instance, the dermatology treatment Zenrelia is now in use at approximately 11,000 U.S. clinics as of the first quarter of 2025. Furthermore, the parasiticides Credelio Quattro and AdTab are critical drivers in this space. Credelio Quattro, a newer offering, is seeing about 70% of its sales come from switches from competitive products as of the third quarter of 2025. Zenrelia achieved approximately 5% market share in countries where it has launched as of the third quarter of 2025.

Pet Owners (dogs and cats) seeking parasiticides and therapeutics

Pet owners are the end-users for many of Elanco Animal Health Incorporated's most popular products, often accessing them through veterinary clinics or retail channels. Revenue from established parasite control brands remains substantial. In the third quarter of 2025, the Advantage^® Family of products contributed $111 million in revenue, and Seresto^® contributed $60 million in revenue. The oral flea and tick treatment AdTab showed continued strong adoption, with third-quarter 2025 sales up over 25% year-over-year.

Livestock Producers (cattle, swine, poultry) globally

This segment focuses on efficiency, disease prevention, and sustainability for food animal production. The Farm Animal business saw its third quarter 2025 revenue reach $583 million. Growth in this area is heavily influenced by key products like Experior for cattle and strong poultry sales globally. Elanco Animal Health Incorporated reported that Experior sales increased approximately 70% in the third quarter of 2025, following over 100% growth in the prior year. On the sustainability front, the number of cows on Elanco Animal Health Incorporated's methane-reducing feed additive Bovaer doubled between February and the first quarter of 2025.

Third-party distributors and independent retailers

Distributors and retailers form the essential channel for product movement, particularly for over-the-counter or non-prescription items, ensuring broad market access. While specific revenue figures for this channel alone aren't broken out separately from the Pet Health or Farm Animal segments, their role is implied in the overall sales structure. The company achieved market share gains in global pet retail sectors in 2024. The third quarter 2025 results showed that Farm Animal organic constant currency revenue growth included a 2% increase from price, compared to the third quarter of 2024, while Pet Health revenue included a 1% decrease from price.

Here's a look at the reported revenue contribution by the two main segments for Q3 2025:

Customer Segment Group	Q3 2025 Reported Revenue	Year-over-Year Reported Growth (Q3 2025 vs Q3 2024)
Pet Health	$533 million	10%
Farm Animal	$583 million	12%
Total Reported Revenue	$1,137 million	10%

Finance: review the Q4 2025 distributor inventory levels against the full-year guidance of $4,645 million to $4,670 million by next Tuesday.

Elanco Animal Health Incorporated (ELAN) - Canvas Business Model: Cost Structure

You're looking at the cost side of Elanco Animal Health Incorporated's operations as of late 2025. The structure is heavily weighted toward supporting a pipeline of new products and maintaining a global commercial footprint. Honestly, the costs reflect a company in a significant investment phase, trying to translate R&D into market share.

High R&D expenditure to fuel the 170+ program pipeline. While the exact pipeline size of 170+ programs isn't confirmed in the latest reports, the commitment to innovation is clear through the raised financial targets. Elanco Animal Health Incorporated is pouring resources into getting new products like Credelio Quattro and Zenrelia to market, which directly impacts operating costs.

Operating expenses increasing by approximately 8% for innovation launches. For the full year 2025 guidance, Elanco Animal Health Incorporated now expects operating expenses to increase by approximately 8% year over year in constant currency, which is up from a previous expectation of 7%. This incremental strategic investment is specifically tied to the global launches of the innovation portfolio.

Cost of Goods Sold (COGS) implied by 54.9% to 55.2% adjusted gross margin. The cost to produce the goods sold is inversely related to the expected adjusted gross margin for the full year 2025, which management raised to a range of 54.9% to 55.2%. This implies a COGS range of approximately 44.8% to 45.1% of revenue.

The third quarter of 2025 saw the adjusted gross margin percentage land at 53.1%, a 90 basis point increase compared to the third quarter of 2024.

Significant interest expense on debt, though deleveraging is a priority. Debt servicing remains a notable cost. The company has been actively managing this, including the strategic refinancing of a $2.1 billion term loan to extend maturities through 2032. Interest expense figures for recent periods show this cost:

Metric	Value (Millions USD)
Interest Expense (2024)	$247
Interest Expense (2025 Projection)	$243
Interest Expense (2026 Projection)	$205

The net leverage ratio as of September 30, 2025, was 3.7x Adjusted EBITDA, an improvement from 0.6x lower than December 31, 2024. The year-end 2025 net leverage ratio target was improved to 3.7x to 3.8x.

Selling, General, and Administrative (SG&A) costs for global sales force. The costs associated with the global sales force and general operations are substantial, driven partly by the need to support new product launches. For the twelve months ending June 30, 2025, Elanco Animal Health Incorporated's SG&A expenses were $1.364 billion, representing a 5.25% increase year-over-year.

Here's a quick look at some key cost-related metrics as of late 2025:

• Selling, General, and Administrative Expenses (TTM ending June 30, 2025): $1.364 billion.
• Expected Operating Expense Increase (Full Year 2025): Approximately 8% in constant currency.
• Expected Adjusted Gross Margin (Full Year 2025): 54.9% to 55.2%.
• Capital Expenditure (2025 Expectation): About $250 million.
• Estimated Tariff Impact (Full Year 2025): $10 million to $14 million.

Finance: draft 13-week cash view by Friday.

Elanco Animal Health Incorporated (ELAN) - Canvas Business Model: Revenue Streams

The revenue streams for Elanco Animal Health Incorporated are anchored in the sales of its diverse portfolio across companion and food animal health sectors, supplemented by strategic monetization of intellectual property.

The company has raised its full-year 2025 revenue guidance to a range of $4.645 billion to $4.670 billion, reflecting strong momentum through the third quarter of 2025.

Sales of Pet Health products contribute significantly, with reported revenue reaching $533 million in the third quarter of 2025, representing an 8% increase on an organic constant currency basis. Key products driving this include innovations like Credelio Quattro, which achieved approximately 10% share of U.S. broad-spectrum product sales into veterinary clinics in the first quarter of 2025, and Zenrelia, which was in use at about 11,000 U.S. clinics as of the first quarter of 2025.

Farm Animal product sales generated reported revenue of $593 million in the third quarter of 2025, marking a 10% increase on an organic constant currency basis, driven by volumes across cattle and poultry. Experior is noted as one of the innovation products contributing to positive momentum in the Farm Animal segment.

Innovation revenue, which includes the commercialization of new products, is now targeted for the full year 2025 to be between $840 million and $880 million. This is an increase from earlier guidance, reflecting positive momentum for products like Credelio Quattro, Experior, AdTab, and Zenrelia.

Royalty and milestone payments from licensing agreements provide an additional stream, notably following the agreement announced in May 2025 to monetize certain U.S. royalties and commercial milestones associated with lotilaner (XDEMVY) to Blackstone for an upfront payment of $295 million in cash. The company expected to relinquish approximately $10 million in royalty revenues for 2025 as part of this deal.

Here's a quick look at the updated full-year 2025 financial guidance points:

Financial Metric	Guidance Range (Full Year 2025)
Total Revenue	$4.645 billion to $4.670 billion
Innovation Revenue Target	$840 million to $880 million
Adjusted EBITDA Guidance	$880 million to $900 million

The revenue generation is supported by the performance of specific product categories:

• Sales of Pet Health products, with Q3 2025 revenue at $533 million.
• Sales of Farm Animal products, with Q3 2025 revenue at $593 million.
• Revenue from innovation portfolio launches.
• Income from royalty and milestone payments.

The Pet Health segment saw its third-quarter growth driven by:

• Organic constant currency revenue growth of 8%.
• A 1% decrease from price, in line with expectations.

The Farm Animal segment's third-quarter growth included:

• Reported revenue of $593 million.
• Organic constant currency revenue growth of 10%.
• A 1% increase from price compared to the third quarter of 2024.

Finance: draft 13-week cash view by Friday.